FPT Partners with OutSystems to Accelerate Adoption of Low-Code Platforms in Japan
4.5.2020 12:59:00 EEST | Business Wire | Press release
Vietnam’s largest tech firm FPT has recently signed the Managed Services Partner agreement with global software firm OutSystems, a strategic move that helps both sides strengthen foothold in the Japanese market through low-code platforms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200504005316/en/
FPT and OutSystems senior executives met at Tokyo last August to discuss strategic partnership (Photo: Business Wire)
Being the first Managed Services Partner of OutSystems in Japan, FPT will provide a comprehensive range of services from development, operations to maintenance of software applications on its low-code platform. Low code, as defined by is OutSystems, is a software development approach that enables faster delivery of applications, hence faster time-to-market.
According to Mr. Arnold Consengco, OutSystems’s Northeast Asia and Japan Regional Vice President, the partner choice is a testament to FPT’s strength not only in terms the of digital workforce but also technological capabilities.
“FPT has a large number of resources, multi-language capabilities as well as a strong position in the Japanese market since it is a very large base for the company. I believe it has a lot to offer and to bring that offshore development capability to Japan,” he said.
Low-code has helped OutSystems customers achieve exceptional results, from a 253 percent increase in returning on investment in seven months to launching 60 apps in less than two years, saving 650 days of development efforts.
By 2024, low-code application development will be responsible for more than 65 percent of application development activities globally, according to a report released by Gartner last year. Asia Pacific, including Japan, is expected to record the fastest growth in 2019-2024.
“This is where I believe both companies could leverage our resources and build a bigger ecosystem to deliver more projects to more customers. The future basis for commercial engagement with customers in Japan is not based on how cheap you can do something, but rather, how fast you can do it,” Arnold said.
“With labor shortage, Japanese businesses have actively adopted digital technologies such as low code to enhance their productivity and competitiveness. We really look forward to working with OutSystems to accelerate digital transformation in the country,” said FPT Chairman Dr. Truong Gia Binh.
Since entering Japan in 2005, FPT has dedicated nearly 10,000 employees, both working onsite and offshore, to helping local companies address their digital challenges. The company is set to become the global top 50 world-class provider of comprehensive digital services and solutions by 2030.
About FPT Corporation
FPT Corporation is a global leading technology and IT services provider headquartered in Vietnam, with nearly US$1.2 billion in revenue and 29,000 employees. As a pioneer in digital transformation, FPT delivers world-class services in Smart factory, Digital platforms, RPA, AI, IoT, Enterprise Mobility, Cloud, AR/VR, Embedded Systems, Managed services, Testing, Platform modernization, Business Applications, Application Services, BPO, and more. The company has served over 700+ customers worldwide, a hundred of which are Fortune Global 500 companies in the industries of Aerospace & Aviation, Automotive, Banking and Finance, Logistics & Transportation, Utilities and more. For more information, please visit www.fpt-software.com.
About OutSystems
Thousands of customers worldwide trust OutSystems, the number one low-code platform for rapid application development. Engineers with an obsessive attention to detail crafted every aspect of the OutSystems platform to help organizations build enterprise-grade apps and transform their business faster. OutSystems is the only solution that combines the power of low-code development with advanced mobile capabilities, enabling visual development of entire application portfolios that easily integrate with existing systems. To learn more, please visit: www.outsystems.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200504005316/en/
Contact information
Media
Hue Le (Ms.)
FPT Corporation
Email: hueltm@fsoft.com.vn
Mobile: +84866867745
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom